๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Flow cytometric evidence for minimal residual disease and cytological heterogeneities in acute lymphoblastic leukemia with severe hypodiploidy

โœ Scribed by Dr. Masahito Tsurusawa; Yasuhiko Kaneko; Naoyuki Katano; Makoto Niwa; Mari Ito; Takeo Fujimoto


Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
703 KB
Volume
32
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

โœฆ Synopsis


Two subpopulations of small and large leukemia cells and binucleated cells were present in the bone marrow of a 10-year-old girl with acute lymphoblastic leukemia (ALL). Cytogenetic studies showed some cells with a karyotype of 34,X,-X,-2,-3,-4,-5,-7,-9, -13,-15,-16,-17,-20, and others with a karyotype that was exactly double the chromosome set in the cells with 34 chromosomes. Flow cytometric (FCM) examination of surface common ALL antigen (CALLA) and DNA content of the lymphoblasts led to the identification of the primary hypodiploid DNA stemline (DI = 0.72), which corresponds to the small-sized blasts, and the secondary hyperdiploid DNA stemline (DI = 1.44), which corresponds to the large-sized blasts. Sequential bone marrow examinations with FCM and cytogenetics revealed the persistence of the primary hypodiploid clone during remission and their proliferation with chromosomal evolution at full retapse. These results suggest that more rational inductive therapy should be designed to achieve the favorable outcome of ALL with severe hypodiploidy and that FCM is a useful tool to monitor the minimal residual disease of this subgroup in ALL.


๐Ÿ“œ SIMILAR VOLUMES


The use of receiver operating characteri
โœ Adhra Al-Mawali; David Gillis; Ian Lewis ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 461 KB ๐Ÿ‘ 2 views

## Abstract ## Background: Multiparameter flow cytometry (MFC) has been shown to be a useful approach for detection of minimal residual disease (MRD). The aim of the study was to determine the optimal threshold that can separate patients into two groups in terms of leukemic residual cells and rela